Insights into Lipid-Based Delivery Nanosystems of Protein-Tyrosine Kinase Inhibitors for Cancer Therapy

According to the WHO, cancer caused almost 10 million deaths worldwide in 2020, i.e., almost one in six deaths. Among the most common are breast, lung, colon and rectal and prostate cancers. Although the diagnosis is more perfect and spectrum of available drugs is large, there is a clear trend of an...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutics 2022-12, Vol.14 (12), p.2706
Main Authors: Jampilek, Josef, Kralova, Katarina
Format: Article
Language:English
Subjects:
Antibiotics
anticancer
Apoptosis
Biology
Cancer
Cancer therapies
Care and treatment
Cell division
Cell growth
Chemotherapy
Disease
Drug delivery systems
Drugs
Kinases
Leukemia
Lipids
Materials
Monoclonal antibodies
Mutation
nanoemulsions
Nanoparticles
Phosphatase
Phosphorylation
Physiology
protein-tyrosine kinase
Proteins
Review
self-nanoemulsifying drug delivery systems
Signal transduction
Structure
tyrosine kinase inhibitors
Vehicles
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:According to the WHO, cancer caused almost 10 million deaths worldwide in 2020, i.e., almost one in six deaths. Among the most common are breast, lung, colon and rectal and prostate cancers. Although the diagnosis is more perfect and spectrum of available drugs is large, there is a clear trend of an increase in cancer that ends fatally. A major advance in treatment was the introduction of gentler antineoplastics for targeted therapy-tyrosine kinase inhibitors (TKIs). Although they have undoubtedly revolutionized oncology and hematology, they have significant side effects and limited efficacy. In addition to the design of new TKIs with improved pharmacokinetic and safety profiles, and being more resistant to the development of drug resistance, high expectations are placed on the reformulation of TKIs into various drug delivery lipid-based nanosystems. This review provides an insight into the history of chemotherapy, a brief overview of the development of TKIs for the treatment of cancer and their mechanism of action and summarizes the results of the applications of self-nanoemulsifying drug delivery systems, nanoemulsions, liposomes, solid lipid nanoparticles, lipid-polymer hybrid nanoparticles and nanostructured lipid carriers used as drug delivery systems of TKIs obtained in vitro and in vivo.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics14122706